Thyrotropin-releasing hormone (TRH) is a peptide hormone released from hypothalamic tissue and stimulates the release of thyroid-stimulating hormone (thyrotropin) from the mammalian anterior pituitary by binding to the TRH receptor on the cell surface of the pituitary.
But the cytosolic peptidases are generally considered to have no role in the metabolism of these bioactive peptides, because neuropeptides are commonly hydrolyzed by ectoenzymes localized on the membrane of cells with the active site facing the extracellular space or by lysosomal peptidases after endocytosis. 1, 11) Nevertheless, the contribution of cytosolic PAP-I to the hydrolysis of TRH in vivo is controversial. Charli et al. 6) reported that pGlu diazomethyl ketone, a PAP-I inhibitor, did not enhance TRH levels in the brain in vivo or in vitro, but Faivre-Bauman et al. 12) observed increased levels of TRH when primary cultures of hypothalamic cells were treated with Z-Gly-ProCHN 2 , also known as a PAP-I inhibitor.
Recently we expressed the functional forms of rat, mouse and human PAP-Is by Escherichia coli as a single protein and obtained an antibody raised against rat recombinant PAP-I. 13) Using these preparations, we showed that L-pGlu p-nitroanilide (L-pGlu-pNA) is a good non-peptide synthetic substrate for recombinant PAP-Is and is hydrolyzed solely by cytosolic PAP-I from the immunoprecipitation study using the antibody. 13) We also demonstrated that the liver and kidney show relatively high PAP-I activities compared with other tissues tested. 13) More recently we found that PAP-I is involved in the hydrolysis of some xenobiotic compounds having an LpGlu or L-pGlu-related structure, now under development in our company. 14, 15) In this study, by using the recombinant PAP-Is and the antibody against rat PAP-I, we investigated the possible contribution of PAP-I to the degradation of TRH in rats based on biochemical experiments in brain subcellular fractions and immunohistochemical localization of PAP-I in the brain as well as the liver and kidney.
MATERIALS AND METHODS
Chemicals TRH, phenacetin, L-pGlu, rabbit IgG reagent grade from serum, bacitracin, 1,10-phenanthroline, His-Prodiketopiperazin (cyclo(His-Pro)), acid TRH, L-proline, L-prolinamide and L-pGlu-pNA were obtained from Sigma Chemical Co. [Proline 3-3,4-3 H]-TRH (50 Ci/mmol) was purchased from American Radiolabeled Chemicals Inc. All other reagents and solvents used were of commercially available, guaranteed grade.
Kinetic Analysis of Hydrolysis of TRH Rat, mouse and human PAP-Is expressed functionally each as a single protein by Escherichia coli as previously described 13) were used as the enzyme source. Incubation experiments using TRH as a substrate and determination of L-pGlu produced from TRH were conducted according to the method of Abe et al.
Subcellular Fractionation of Rat Brain Homogenate
Male F344/DuCrj rat brain was homogenized in three volumes of 10 mM potassium phosphate buffer (pH 7.4) using a Polytron (Kinematica AG). The homogenate was centrifuged at 105000 g for 1 h. The supernatant as the cytosolic fraction was collected and stored frozen at Ϫ80°C until use. The precipitate fraction was re-suspended in the above buffer and centrifuged at 105000 g for 1 h for washing, which was repeated twice. The precipitate fraction was designated as the particulate fraction and stored frozen at Ϫ80°C until use.
Assay Procedure for Hydrolysis of [ 3 H]-TRH and LpGlu-pNA Each enzyme source in 10 mM potassium phosphate buffer (pH 7.4) was preincubated on ice for 0.5-1 h with or without the antibody (final concentration: 1 mg-protein/ml) or 1,10-phenanthroline (final concentration: 1 mM). In the case of measurement of TRH hydrolyzing activity, bacitracin (final concentration: 1 mg/ml) was added to the reaction mixture to specifically inhibit the deamination reaction of TRH.
11) After preincubation at 37°C for 2 min, [ 3 H]-TRH or L-pGlu-pNA was then added to a final concentration of 20 mM and the reaction mixture (50 ml) was incubated at 37°C for 5-30 min. After incubation, the reaction was stopped by the addition of three volumes of 5% trifluoroacetic acid (TFA) for measurement of TRH hydrolyzing activity and of acetonitrile containing 1 mM of phenacetin, the internal standard for determination of pNA by LC/MS/MS, for measurement of L-pGlu-pNA hydrolyzing activity. The mixtures were centrifuged at 20000 g for 2 min at 4°C and the supernatants were stored at 4°C until analysis. TRH and its metabolites were determined by radio-HPLC as described below. In a separate experiment it was confirmed that the bacitracin and the control rabbit IgG did not affect the hydrolyzing activity of TRH at all. The concentrations of pNA produced from L-pGlu-pNA were determined as previously described.
13)
Determination of TRH and Its Metabolites by Radio-HPLC TRH and its metabolites were determined by radio-HPLC according to the method of Kelly et al. 16) with slight modification. A Radiomatic A-500, a flow scintillation analyzer (Packard Instrument Company), connected to an LC-10A system (Shimadzu Corp.) was used as the radio-HPLC system for measurement of [ The flow rate and the temperature of the column oven were set at 1.0 ml/min and 40°C, respectively. UV absorbance was measured at 207 nm. The lower limits of quantification were estimated to be 0.1 mM. Each peak was identified by comparison to the retention time of the standard compounds. The retention time of His-Pro-NH 2 was estimated by that of the peak produced from TRH after incubation with recombinant rat PAP-I. TRH hydrolyzing activity was calculated based on the sum of the TRH mediated metabolites (i.e., L-proline, L-prolinamide, His-Pro-NH 2 , cyclo(His-Pro) and unknown metabolite(s) eluted next to L-proline). All the TRH mediated metabolites other than unknown metabolite(s) were consistent with those reported previously. 2, 11) Immunoblot Analysis Male F344/DuCrj rat liver, kidney and brain cytosolic or microsomal fractions and a polyclonal antibody raised against rat PAP-I in rabbits were prepared as previously described. 13 ) SDS-PAGE analysis of denatured samples (7-28 mg protein) was performed on 12.5% gels according to the method of Laemmli. 17) Immunoelectrophoretic (Western) blot analysis was carried out with polyvinylidene fluoride (PVDF) membranes (Immobilon, Millipore), and the protein was detected by the enhanced chemiluminescence detection method (Phototope-HRP Western Blot Detection Kit, Cell Signaling Technology, Inc.).
Immunohistochemistry Male F344/DuCrj Rats were sacrificed by withdrawing entirely the blood from the abdominal aorta under diethyl ether anesthesia, and the cerebrum, cerebellum, pituitary, liver and kidney were excised. For light microscopic observation, the tissue specimens were fixed in neutral buffered 10% formaldehyde solution. Paraffin sections (4 mm thick) were prepared and stained with hematoxylin.
RESULTS

Kinetic Parameters for TRH Hydrolysis by Recombinant PAP-Is
The K m values for TRH hydrolysis by recombinant rat, mouse and human PAP-Is were 0.056, 0.041 and 0.046 mM, respectively ( Table 1 ). The V max values for recombinant rat, mouse and human PAP-Is were 13.5, 11.5 and 9.9 mmol/min/mgP, respectively. These values were very similar to those for L-pGlu-pNA, as reported previously.
13)
The Effect of Inhibitors on the L-pGlu-Cleaving Activities of Rat Brain Subcellular Fractions The hydrolytic activities toward TRH and L-pGlu-pNA in rat brain subcellular fractions in the presence of an antibody against rat PAP-I and 1,10-phenanthroline are shown in Table 2 . 1,10-phenanthroline, a chelating agent, is known to inhibit the PAP-II activity.
5) The hydrolytic rate toward TRH in the brain homogenate was not inhibited by the addition of the antibody (94.1% of non-adding control activity), but markedly inhibited by the addition of 1,10-phenanthroline (34.2%). These results indicated that PAP-II mainly contributed to the metabolism of TRH in the brain homogenate. The hydrolytic activity toward TRH in the particulate fraction (7.2 nmol/min/g tissue) was much higher than that in the cytosolic fraction (1.7 nmol/min/g tissue) and the activity was almost totally inhibited by 1,10-phenanthroline (7.6%) without being affected by the addition of the antibody (108.2%). The antibody, however, strongly inhibited the hydrolytic activity in the cytosolic fraction (9.2%).
The hydrolytic activity toward L-pGlu-pNA in the brain homogenate was considerably inhibited by the addition of the antibody (20.5%), showing that PAP-I highly contributed to L-pGlu-pNA-hydrolyzing activity in the brain homogenate. This was also supported by the facts that the hydrolytic activity in the cytosolic fraction (2.6 nmol/min/g tissue) was much higher than that in the particulate fraction (0.2 nmol/min/g tissue) and was completely inhibited by the addition of the antibody (0%). The hydrolytic activity toward L-pGlu-pNA in the cytosolic fraction (2.6 nmol/min/g tissue) was comparable to that toward TRH (1.7 nmol/min/g tissue), being consistent with the results of kinetic study as shown in Table 1 . The hydrolytic activity toward TRH in the particulate fraction (7.2 nmol/min/g tissue) greatly exceeded that toward L-pGlupNA (0.2 nmol/min/g tissue), suggesting high specificity of PAP-II toward TRH.
Immunoblotting Analysis of Rat Liver, Kidney and Brain Subcellular Fractions by PAP-I Antibody The cytosolic and microsomal fractions of rat liver, kidney and brain were analyzed by immunoblotting using an antibody raised against recombinant rat PAP-I (Fig. 1 ). An immunoreactive band with size of 25 kDa, nearly coinciding with the molecular weight of rat PAP-I (22.9 kDa 13) ), was detected most intensely in the cytosolic fraction of the kidney. The immunoreactive band was also found in the cytosolic fractions of the liver and brain, but the intensity in the brain cytosolic fraction was only detectable when quadruple protein amount of the kidney and liver was applied. This band could not be detected in the microsomal fraction of the liver, kidney or brain.
Immunohistochemical Localization of PAP-I The immunohistochemical localization of immunoreactive proteins with the antibody against rat PAP-I in the cerebrum, cerebellum, pituitary, liver and kidney in rats is shown in Fig. 2 . Diffusible staining was observed in the cerebrum (A) and cerebellum (B). Partially distinct antibody staining was seen in the pituitary (C), the target tissue of TRH, but the staining was observed intracellularly.
The enzyme was uniformly distributed in the liver (D). In the kidney (E), distinct antibody staining was observed in the proximal convoluted tubules. Less distinct staining was seen in the distal tubules. No significant staining was detected in the renal glomeruli.
DISCUSSION
We investigated the possible contribution of PAP-I toward TRH metabolism in the rat brain based on biochemical experiments and an immunohistochemical localization study using, for the first time, recombinant PAP-Is and an antibody against rat PAP-I.
The K m values for TRH hydrolysis by recombinant rat, mouse and human PAP-Is were 0.056, 0.041 and 0.046 mM, respectively, and those for L-pGlu-pNA hydrolysis were 0.054, 0.038 and 0.038 mM, showing that the affinities of TRH and L-pGlu-pNA to recombinant PAP-Is are almost the same among these species. Schomburg et al. 18) and Gallagher et al. 19) reported that K m values for TRH hydrolysis by recombinant human PAP-II and purified bovine brain PAP-II were 0.030 and 0.040 mM, respectively. These K m values are similar to the K m values by the PAP-Is in our study, indicating that the affinity toward TRH is equivalent between PAP-I and PAP-II.
However the inhibition experiments in the brain subcellular fractions as shown in Table 2 clearly indicated that particulate PAP-II, rather than cytosolic PAP-I, is predominantly involved in the metabolism of TRH. The L-pGlu-cleaving activity toward L-pGlu-pNA was almost all distributed in the cytosolic fraction and was markedly inhibited by the addition of the antibody against rat PAP-I. In contrast, the L-pGlucleaving activity toward TRH was mainly distributed in the particulate fraction and was inhibited by the addition of a PAP-II inhibitor 1,10-phenanthroline, but not by the addition of the antibody against rat PAP-I. Note that there still remains the possibility of contribution of unidentified metalloenzymes which can hydrolyze toward TRH.
PAP-II has been demonstrated to localize primarily in the central nervous system as a membrane-anchored ectoenzyme and has narrow substrate specificity toward TRH. 2, 4, 5) Higher specific activity levels of PAP-II are found in the cerebral cortex, olfactory bulb, hippocampus and cerebellum, but lower levels are present in the spinal cord. 6, 20, 21) Heuer et al. 3) have demonstrated that basal PAP-II activity in the pituitary is very low, but the activity and the mRNA levels of adenohypophyseal PAP-II are dramatically increased by thyroid hormones, whereas PAP-II activities in other brain regions are not, showing that adenohypophyseal PAP-II activity is stringently regulated by thyroid hormones. These findings strongly suggest a physiological role of this peptidase for the regulation of the biological activity of neuronally released TRH. 2, 3, 19) On the other hand, immunoblot analysis showed the cytosolic distribution of PAP-I, being consistent with the subcellular localization of PAP-I activity in rat liver. 13) Immunohistochemical localization study of PAP-I demonstrated intracellular distribution in the pituitary, the target tissue of TRH. Since neuropeptides are believed not to generally access the cytosolic compartment, the cytosolic distribution of PAP-I revealed that PAP-I might not contribute to the hydrolysis of TRH. However, interestingly, the distribution of PAP-I in the pituitary was heterogeneous, although that of the cerebrum and cerebellum was homogenous. Friedman et al. 20) also showed that the cytosolic PAP-I was highest in the pituitary among the brain regions tested. Because the pituitary is composed of functionally dissimilar cells, the heterogeneous PAP-I distribution observed suggested that there is a certain specific function of PAP-I in the subpopulation of the cells in the pituitary. It will be interesting to elucidate the possible functions of PAP-I at this site and the findings of future studies are awaited.
The physiological role of PAP-I toward L-pGlu-terminating neuropeptides currently remains unclear. As a possible role of brain PAP-I, Cummins et al. 1) suggested that cytosolic degradation of neuropeptides might represent a security mechanism to degrade neuropeptides produced in excess, in cases where secretion from neuropeptide-synthesizing cells is suppressed. Gandarias et al. 22) suggested that cytosolic PAP-I could play a part in the normal development and the maturation of the rat central nervous system. Peptides can act as autocrine factors in brain development and intracellular peptidases, including PAP-I, undergo drastic changes during brain ontogeny. 23, 24) Furthermore He et al. 25) reported that PAP-I may be involved in the propensity of amyloid precursors to form insoluble plaques, resulting in Alzheimer-type diseases.
Immunohistochemical localization study of PAP-I has also demonstrated localization specifically in the renal proximal convoluted tubules in the kidney, suggesting the possibility that PAP-I contributes to degradation of the peptides affecting functions of the renal proximal convoluted tubules. Since PAP-I activity is high in the kidney, which is the general catabolic tissue of many peptides, and PAP-I activity is widely distributed in such functionally dissimilar tissues as the liver, kidney, brain and skeletal muscle, in addition to its 1200 Vol. 27, No. 8 broad substrate specificity, researchers have speculated that PAP-I might play an important role in the final catabolism of peptides to free amino acids, regulating the level of free LpGlu in the cell. 1, 26, 27) In this regard, it is noteworthy that free L-pGlu is known to have pharmacological properties such as prevention of scopolamine-induced amnesia in rats, while elevated levels of free L-pGlu have been demonstrated in certain disease states. 1) Furthermore Awade et al. 26) have suggested that high concentrations of L-pGlu-blocked peptides are cytotoxic and thus PAP-I plays a detoxification role.
In conclusion, we found that PAP-I was distributed intracellularly in the pituitary, the target tissue of TRH, indicating that PAP-I might not be dominantly involved in the degradation of TRH in rats. We also found PAP-I was heterogeneously distributed in the pituitary and localized in the renal proximal tubules. Further studies, including studies using knockout mice, are needed to determine the function of PAP-I in these restricted sites and its physico-pathological significance.
